公开(公告)号：US20240101666A1

公开(公告)日：2024-03-28

申请号：US18033200

申请日：2021-10-22

Applicant: Bristol-Myers Squibb Company

Inventor： Laurence David TOMS ,  Paul Andrew BASCIANO

IPC: C07K16/28 ,  A61K31/282 ,  A61K31/337 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K31/282 ,  A61K31/337 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/507

Abstract: The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).

公开(公告)号：US20240066123A1

公开(公告)日：2024-02-29

申请号：US18336889

申请日：2023-06-16

Applicant: Bristol-Myers Squibb Company

Inventor： Lori S. BURTON ,  William Ying ,  Nils Lonberg ,  Sudhir Chakravarthi ,  Pedro Smith

IPC: A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  C07K16/28

CPC classification number: A61K39/39591 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  A61J1/1412

Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.

公开(公告)号：US20240051996A1

公开(公告)日：2024-02-15

申请号：US17943532

申请日：2022-09-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gardner S. CREECH ,  Mahboubeh KHEIRABADI ,  Martin D. EASTGATE ,  David S. NIRSCHL ,  Percy H. CARTER

IPC: C07K7/64 ,  C07C309/75 ,  C07C309/77 ,  C07D225/08 ,  C07K1/04 ,  C07K1/107 ,  C07K17/08

CPC classification number: C07K7/64 ,  C07C309/75 ,  C07C309/77 ,  C07D225/08 ,  C07K1/042 ,  C07K1/1077 ,  C07K17/08

Abstract: The disclosure is directed to the synthesis and improved methods for purifying macrocyclic peptides produced by solid phase peptide synthesis.

公开(公告)号：US20240050564A1

公开(公告)日：2024-02-15

申请号：US18271579

申请日：2022-01-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yu LIU ,  Sarah TANNENBAUM-DVIR

IPC: A61K39/395 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with lung cancer, such as small cell lung cancer, comprising administering to the subject various combinations of an anti-fucosyl-GM1 antibody, an immunomodulatory agent, such as a PD-1/PD-L1 antagonist, such as an antagonist anti-PD-1 or anti-PD-L1 antibody, carboplatin and etoposide.

公开(公告)号：US11884650B2

公开(公告)日：2024-01-30

申请号：US17743615

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US11878975B2

公开(公告)日：2024-01-23

申请号：US16955097

申请日：2018-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  John L. Gilmore ,  Tasir Shamsul Haque ,  Trevor C. Sherwood ,  Brian K. Whiteley ,  Shoshana L. Posy ,  Sreekantha Ratna Kumar ,  Laxman Pasunoori ,  Srinivasan Kunchithapatham Duraisamy ,  Subramanya Hegde ,  Rushith Kumar Anumula ,  Pitani Veera Venkata Srinivas

IPC: C07D471/08 ,  C07D487/08 ,  C07D519/00 ,  C07D471/04 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/02 ,  C07D487/04 ,  C07D491/08

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/02 ,  C07D487/04 ,  C07D491/08

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20240002513A1

公开(公告)日：2024-01-04

申请号：US18251935

申请日：2021-11-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Leonard P. JAMES ,  Yougan CHENG ,  Brian J. SCHMDIT ,  John J. ENGELHARDT ,  Li LI

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/41 ,  A61K2039/545

Abstract: The present invention provides methods of dosing and administration of non-fucosylated anti-CTLA-4 antibodies, such as non-fucosylated ipilimumab, as monotherapy, and related compositions and dosage forms.

公开(公告)号：US20240002512A1

公开(公告)日：2024-01-04

申请号：US18052076

申请日：2022-11-02

Applicant: Bristol-Myers Squibb Company

Inventor： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574

CPC classification number: C07K16/2818 ,  C07K16/2827 ,  A61K39/3955 ,  C07K16/18 ,  C07K16/2803 ,  G01N33/57492 ,  A61K2039/505

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US20230416388A1

公开(公告)日：2023-12-28

申请号：US18133822

申请日：2023-04-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Suba KRISHNAN ,  Penny E. PHILLIPS ,  Zheng YANG ,  Haiqing WANG

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/507

Abstract: Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of an anti-GITR antibody alone or together with an anti-PD-1 or anti-PD-L1 antibody.

公开(公告)号：US11844927B2

公开(公告)日：2023-12-19

申请号：US17770682

申请日：2020-10-21

Applicant: Bristol-Myers Squibb Company

Inventor： Martin John McLoughlin

IPC: A61M5/145 ,  A61M5/168

CPC classification number: A61M5/145 ,  A61M5/16804 ,  A61M2205/3553

Abstract: In one aspect, a system is provided of verifying the accuracy of a plurality of serially-connected drug modules of a combinatorial drug delivery device, each of the drug modules including a drug reservoir, the system including: a machine-readable code located on each of the drug modules; application software configured to generate an activation code based on the machine-readable codes and the sequence of the machine-readable codes; a flow controller on the drug delivery device which is selectively actuatable to a use state to permit flow of drug from the drug delivery device; and, a control unit on the drug delivery device having a computing processing unit configured to compare the activation code with an authentication code, and, wherein, if the authentication code matches the activation code, the computing processing unit causes actuation of the flow controller to permit flow of the drug from the drug delivery device.